RxDoctor Payments Data

Myra Reed, MD

Adult Medicine · Panama City Beach, FLNPI 1215996434

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $14,253 of the $15,896 with a category attached, or 89.7%. Orthofix Medical, Inc. accounts for 89.7% of it on its own, with 12 other manufacturers making up the rest. Among adult medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,896in general payments, 2019–2025

Across 78 payments — averaging $203.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orthofix Medical, Inc.$14K
  • Novo Nordisk$583
  • Galderma Laboratories, L.p.$412
  • Lilly USA, LLC$200
  • AbbVie$127
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$94
  • plus $228 from 7 others

What the payments were for

  • Royalty or licence$14,25390%
  • Speaking & faculty fees$1501%
  • Food & beverage$1,4939%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,896 in reported general payments places this provider in the 95th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Medicare billing

Part B allowed, 2024
$35,171
Medicare patients
69
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$40,106
EliquisApixaban22$19,161
MyrbetriqMirabegron12$6,697
SynthroidLevothyroxine Sodium30$2,671
ProgesteroneProgesterone, Micronized44$1,897
Estradiol (Twice Weekly)Estradiol17$1,250
Liothyronine Sodium19$749
Rosuvastatin Calcium60$709
Ezetimibe28$647
FenofibrateFenofibrate,micronized15$622
Levothyroxine Sodium49$618
Nystatin12$553
Losartan Potassium20$398
Metoprolol Succinate12$393
Valsartan13$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$200$40,10630 claims
AbbVieSynthroid$127$2,67130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 adult medicine providers in Florida.

Other adult medicine in Panama City Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →